Integra LifeSciences Holdings (IART)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -6,943 | -6,544 | 23,648 | 40,234 | 67,741 | 100,853 | 131,271 | 171,875 | 180,550 | 172,988 | 166,302 | 156,582 | 169,075 | 216,435 | 205,543 | 170,106 | 133,892 | 56,467 | -3,480 | 26,625 |
| Total stockholders’ equity | US$ in thousands | 1,545,280 | 1,521,590 | 1,534,200 | 1,597,950 | 1,587,880 | 1,579,220 | 1,683,160 | 1,674,940 | 1,804,400 | 1,724,410 | 1,660,920 | 1,615,200 | 1,684,800 | 1,631,690 | 1,574,980 | 1,529,330 | 1,514,870 | 1,397,990 | 1,349,100 | 1,341,800 |
| ROE | -0.45% | -0.43% | 1.54% | 2.52% | 4.27% | 6.39% | 7.80% | 10.26% | 10.01% | 10.03% | 10.01% | 9.69% | 10.04% | 13.26% | 13.05% | 11.12% | 8.84% | 4.04% | -0.26% | 1.98% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-6,943K ÷ $1,545,280K
= -0.45%
Integra LifeSciences Holdings' return on equity (ROE) has shown fluctuating trends over the past few years.
The ROE was relatively low at the beginning of the analyzed period, standing at 1.98% as of March 31, 2020. It dipped slightly into negative territory at -0.26% by June 30, 2020 before starting to recover.
There was a significant improvement in ROE by December 31, 2020, reaching 8.84%, indicating a positive turn in the company's profitability and efficiency in utilizing shareholders' equity to generate profits.
The trend continued to improve through the first half of 2021, with ROE reaching double digits at 13.05% by June 30, 2021. Subsequently, ROE remained relatively stable around the 10-13% range for the rest of 2021 and the beginning of 2022.
However, there was a slight decline in ROE starting from June 30, 2022, which continued through the end of 2024. By December 31, 2024, the ROE had declined to -0.45%, indicating a decrease in the company's ability to generate profits from shareholders' equity.
Overall, Integra LifeSciences Holdings' ROE performance has been variable, with periods of both improvement and decline. Investors and analysts may want to further investigate the factors contributing to these fluctuations to assess the company's financial health and performance.
Peer comparison
Dec 31, 2024